Skip to content
2000
Volume 21, Issue 18
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Doxorubicin (DOX) is widely used as a clinical first-line anti-cancer drug. However, its clinical application is severely limited due to the lack of tumor specificity of the drug and severe side effects such as myelosuppression, nephrotoxicity, dose-dependent cardiotoxicity, and multi-drug resistance. To improve the bioavailability of DOX, maximize the therapeutic effect, and reduce its toxicity and side effects, many studies have been done on the nanoformulations of DOX, such as liposomes, polymer micelles, dendrimer, and nanogels. Herein, we review the latest progress of DOX nano-preparations and their anti-tumor effects, hoping to provide theoretical references and new research ideas for the development of new dosage forms of the drug and the technical methods available for clinical application.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520621666201229115612
2021-12-01
2025-05-07
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520621666201229115612
Loading

  • Article Type:
    Review Article
Keyword(s): Doxorubicin; drug delivery systems; nanocarrier; nanoparticles; nanotechnology; synthesis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test